Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 6.54%, which has investors questioning if this is right time to buy ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

OP-3136 showed activity that was independent of KAT6 amplification or over expression. In the OVCAR3 model, OP-3136 monotherapy demonstrated sustained tumor regression across the 28-day study period ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough ...

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...